Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: A deficiency of NK cells, but not an NK cell deficiency by El-Sherbiny, YM et al.
	



	

		

		
		



		

	

	
				
 

!∀#∃%&∋(&)

%&∗(&+%&,&−&.&−/&01

&∗0234567	
27+6	

8%/
	/
9
∃.%
7+&
∃	
	7+%:

&53265;5∀5;3<##7444=∀> 5
		8

954553∃

∀345∀4 ∀>53
	

	





	?	

				

Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria; a 
deficiency of NK cells, but not an NK cell deficiency.  
To the editor; 
Treatment of the glycosylphosphatidylinositol (GPI) anchor-deficiency, paroxysmal 
nocturnal hemoglobinuria (PNH), has been revolutionized by use of the anti-C5 
antibody eculizumab, which blocks complement-mediated hemolysis and the 
associated pathology.
1,2
 In addition to complement susceptibility, GPI-anchor 
deficiency alters cellular function with the potential to further contribute to disease. 
For example, defective natural killer (NK) cell activity in PNH was first described 
more than three decades ago.
3,4  
NK cell deficiencies are associated with susceptibility 
to infection
5,6
, suggesting that NK function in PNH should be analyzed in more detail.  
Here we show that functional defects in NK cell activity in PNH result from reduced 
NK cell numbers rather than cell intrinsic defects. 
Early PNH studies showed that impaired NK cell activity was associated with reduced 
large granular lymphocyte (LGL) counts.
3,4
 However, these reports preceded the 
definition of NK cells and our understanding of the molecular basis of PNH, 
prompting reassessment. Mosaicism in PNH
1
 allows side-by-side functional 
comparisons of GPI+ and GPI
neg
 NK cells within individual patients, enabling the 
assessment of NK cell activity on a per cell basis (Figure 1 and Supplemental Figure 
1). Despite reports of impaired activity
3,4
, the GPI-deficient NK cells were proficient 
at target cell induced granule exocytosis (Figure 1A-B and Supplemental Figure 1). 
Thus, early findings associating reduced NK cell activity with reduced LGL numbers 
rather than intrinsic cellular activity are correct.
4
 The absolute number of NK cells 
(and more variably, other lymphocytes) are indeed reduced in PNH
7
; in our cohort of 
thirty-nine patients, two thirds had NK cell counts below the reference range (Figure 
1C) and NK cell numbers were not significantly correlated with neutrophil, monocyte 
or platelet counts (Supplemental Figure 2). The basis for reduced NK cell numbers in 
PNH is unclear, although this might be related to impaired chemotactic or 
homeostatic mechanisms, as we recently reported.
8 
Whilst the activity of GPI-
deficient NK cells is unimpaired, a reduction in absolute numbers of NK cells will 
reduce NK cell activity in the blood as a whole. 
 
Clearly, PNH should not be classified as a functional NK cell deficiency (NKD). 
Classical NKD is characterized by approximately one tenth the normal number of NK 
cells and counts in most of our PNH patients exceeded this (Figure 1C). Furthermore, 
the term NKD is reserved for where “the impact upon NK cells need represent the 
major immunological abnormality in the patient”.
6
 In PNH, all hematopoietic lineages 
are affected due to the presence of PIGA mutations in hematopoietic stem cells.
1  
More compelling is the clinical phenotype; the defining feature of NKD is the 
heightened susceptibility to viruses
5,6
 which has not been observed in PNH.
7,9,10
 
Instead, infection in PNH is bacterial in origin
10
 and likely to be associated with 
neutropenia secondary to underlying bone marrow failure or associated with use of 
eculizumab which increases the risk of infection with encapsulated bacteria normally 
eliminated by terminal complement components.
1
 In summary, the low numbers of 
NK cells in PNH affect overall cytotoxicity, but this defect is not severe enough to 
manifest as heightened susceptibility to viral infection as seen in NKD. 
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 Figure 1  
A) NK cell granule exocytosis in PNH. NK cells were purified from blood samples 
from healthy controls (HC) or PNH patients using indirect selection reagents from 
Miltenyi.  NK cell degranulation was assayed using a modification of a standard 
method to allow detection of GPI+ and GPI-deficient NK cells using fluorescent 
aerolysin (FLAER; Ref 8 and Supplemental information). Briefly, purified NK cells 
were co-cultured with K562 target cells (for four hours). Co-cultures were then 
stained with anti-CD56 antibody (to identify NK cells), FLAER to distinguish GPI-
deficient and GPI+ cells and anti-CD107 to identify degranulated NK cells. This 
analysis is from one PNH patient and one healthy control (gating on the purified 
CD56+ NK cells) with the data from the cohort shown in B). We also compared the 
mean fluorescence intensity of CD107 staining in paired GPI-deficient and GPI+ cells 
within each patient. This demonstrated a significant increase in CD107 display on the 
GPI-deficient NK cells (Supplemental Figure 1). 
B) Summary of NK cell degranulation activity from 15 PNH patients and 8 healthy 
controls (HC). The box plot shows the percentage of GPI-deficient (GPI
neg
) and GPI+ 
NK cells that have degranulated in response to target cells. The range (whiskers), 
median (horizontal line) and interquartile range (box) are shown. The percentage of 
CD107+ NK cells was not statistically significant (NS) between any two groups 
according to the Mann Whitney test. Comparison of the percentage of CD107+ NK 
cells within individual patients showed no significant differences between matched 
GPI+ and GPI
neg
 NK cells (Supplemental Figure 1). 
C) Number of total NK cells in 39 PNH patients (cells per microliter). Patient values 
ranged from 3-725 cells per microliter (mean; 100 cells/µl). A European reference 
range (77-427 cells/µl) is shown by the dotted lines. The patients with NK cell counts 
within the normal range were unremarkable in terms of gender, age or treatment 
(ciclosporin or eculizumab). Furthermore, there was no correlation between the NK 
cell counts and the absolute numbers of other cell types (Supplemental Figure 2). 
Peripheral blood samples used in this work were collected after informed consent in 
accordance with the Declaration of Helsinki. 
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i) Supplemental Methods 
 
A modified degranulation assay to analyse responses of GPI-deficient and GPI+ 
NK cells. 
We modified a lymphocyte cytotoxic granule exocytosis assay (Reference S1) to 
include staining with Alexa-488 conjugated aerolysin (Fluorescent aerolysin or 
FLAER from Pinewood Scientific Services, Canada). FLAER binds to intact GPI 
anchors thereby allowing identification of the GPI+ and GPI
neg
 NK cells (Reference 
S2 and S3). NK cells were purified from blood samples from healthy controls (HC) or 
PNH patients using indirect selection reagents from Miltenyi Biotec. This procedure 
typically yields NK cells at >95% purity. Purified NK cells were co-cultured with 
K562 target cells at an effector:target ratio of 2:1 for four hours (in the presence of 
Golgi Stop from BD Biosciences). Co-cultures were then stained with anti-CD56 
antibody (to identify NK cells), FLAER to distinguish GPI
neg
 and GPI+ cells and anti-
CD107 to identify degranulated NK cells.  
Stained cells were analyzed by flow cytometry (using a BD Biosciences LSRII). The 
co-culture contains both NK cells and K562 cells; we gated on the NK cells on the 
basis of their reduced forward and side scatter profile and on the basis of CD56 
expression. Gated NK cells were then analysed for CD107 display on the FLAER
neg
 
(GPI
neg
) and FLAER+ (GPI+) populations.  We analyzed the percentage of GPI+ and 
GPI
neg
 NK cells displaying CD107 on their surface (shown in Figure 1A and B of the 
main manuscript) and the mean fluorescence intensity of the CD107 staining on the 
degranulating GPI+ and GPI
neg
 NK cells (Supplemental Figure 1). 
 
 
 
 
ii) Supplemental Figure 1. 
 
GPI
neg
 NK cells exhibit unimpaired degranulation against K562 target cells 
 
 
The left hand plot shows the mean fluorescence intensity (MFI) of CD107 staining on 
the degranulating GPI+ and GPI
neg
 NK cells following co-culture with K562 target 
cells. The data was analyzed in a pairwise manner, comparing CD107 display in GPI+ 
and GPI
neg
 NK cells within the same patient (joined by lines). Analysis using the 
Wilcoxon matched-pairs signed rank test indicated a significant difference between 
the paired samples, with greater CD107 display shown on the GPI
neg
 population. This 
demonstrates that the GPI-deficient NK cells exhibit enhanced degranulation on a per 
cell level (for example, releasing more granules per cell).  
The right hand plot shows paired samples analyzed according to the percentage of 
CD107+ cells in the GPI+ and GPI
neg
 NK cell populations. This analysis did not 
reveal statistically significant differences (in agreement with the data shown in Figure 
1B of the main manuscript). 
 
 
 
 
 
 
 
iii) Supplemental Figure 2. 
 
A lack of significant correlation between absolute numbers of NK cells and other 
blood cell types in the PNH patient cohort. 
 
 
 
 
The plots show the absolute numbers of total NK cells (encompassing both GPI+ and 
GPI
neg
 populations) on the x-axis, compared to total neutrophils (left hand plot), total 
platelets (center plot) and total monocytes (right hand plot) on the y-axis. Each point 
represents one PNH patient; for neutrophils and platelets, n=39 and for monocytes, 
n=35. Correlation was analyzed using Spearman’s Rank test, no significant 
correlations were observed. 
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